Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Working Capital Changes: 2011-2025

Historic Other Working Capital Changes for Fennec Pharmaceuticals (FENC) over the last 13 years, with Sep 2025 value amounting to -$3.3 million.

  • Fennec Pharmaceuticals' Other Working Capital Changes fell 664.30% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year decrease of 108.47%. This contributed to the annual value of $24.8 million for FY2024, which is 23954.81% up from last year.
  • As of Q3 2025, Fennec Pharmaceuticals' Other Working Capital Changes stood at -$3.3 million, which was down 245.53% from $2.3 million recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Other Working Capital Changes peaked at $25.2 million during Q1 2024, and registered a low of -$3.3 million during Q3 2025.
  • In the last 3 years, Fennec Pharmaceuticals' Other Working Capital Changes had a median value of -$182,000 in 2023 and averaged $2.6 million.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first plummeted by 2,866.67% in 2021, then spiked by 19,371.76% in 2024.
  • Fennec Pharmaceuticals' Other Working Capital Changes (Quarterly) stood at $823,000 in 2021, then tumbled by 79.21% to $492,000 in 2022, then decreased by 14.84% to $419,000 in 2023, then tumbled by 108.10% to -$437,000 in 2024, then tumbled by 664.30% to -$3.3 million in 2025.
  • Its Other Working Capital Changes stands at -$3.3 million for Q3 2025, versus $2.3 million for Q2 2025 and -$636,000 for Q1 2025.